Looking back to 105 days ago, Fulcrum Therapeutics Inc (NASDAQ:FULC) priced a 4,000,000 share secondary stock offering at $11.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time. In trading on Tuesday, bargain hunters could buy shares of FULC and achieve a cost basis 2.6% cheaper than those buyers, with shares changing hands as low as $10.71 per share.
Secondaries can often present buying opportunities for bullish investors interested in purchasing shares, because the sudden extra supply of stock tends to require that the offering be priced at an attractive discount to where the stock had previously been trading before the offering announcement. At last check, Fulcrum Therapeutics Inc shares are currently trading down about 5.5% on the day. The chart below shows the one year performance of FULC shares, versus its 200 day moving average:
Looking at the chart above, FULC's low point in its 52 week range is $7.01 per share, with $22.39 as the 52 week high point — that compares with a last trade of $10.74.
This Article's Word Cloud:BuyersDaysDollarsFULCFulcrumJoinLookingOfferOfferingsRecentSecondariesSecondarySevenSpecialStartStockTherapeuticsTuesdayValueForumaboutaboveachieveannouncementattractiveaveragebackbargainbasisbecausebeenbeforebelowbullishbuyersbuyingchangingchartcheaperinvestmentlastofferingpointpricedsharesharesstockthattradingweekwith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.